NanoVibronix Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor NanoVibronix te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

Dec 09

NanoVibronix receives extension to satisfy Nasdaq bid price requirement

Oct 19

NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

Sep 23

NanoVibronix announces expansion of distribution pact for its ultrasound devices

Dec 11

NanoVibronix secures $6M in equity capital

Dec 02

NanoVibronix reports Q3 results

Nov 17

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat NanoVibronix onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:NAOV - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2024	3	-3	-2	-2	N/A
6/30/2024	3	-3	-2	-2	N/A
3/31/2024	3	-3	-3	-3	N/A
12/31/2023	2	-4	-4	-4	N/A
9/30/2023	1	-5	-4	-4	N/A
6/30/2023	1	-5	-6	-6	N/A
3/31/2023	1	-5	-6	-6	N/A
12/31/2022	1	-5	-7	-7	N/A
9/30/2022	2	-6	-7	-7	N/A
6/30/2022	2	-12	-5	-5	N/A
3/31/2022	2	-10	-5	-5	N/A
12/31/2021	2	-14	-4	-4	N/A
9/30/2021	1	-13	-5	-5	N/A
6/30/2021	1	-7	-5	-5	N/A
3/31/2021	1	-8	-3	-3	N/A
12/31/2020	1	-4	-3	-3	N/A
9/30/2020	1	-5	-3	-3	N/A
6/30/2020	1	-4	-4	-4	N/A
3/31/2020	1	-4	-4	-4	N/A
12/31/2019	1	-6	-4	-4	N/A
9/30/2019	0	-6	-4	-4	N/A
6/30/2019	0	-6	-3	-3	N/A
3/31/2019	0	-6	-4	-4	N/A
12/31/2018	0	-4	-4	-4	N/A
9/30/2018	0	-5	-3	-3	N/A
6/30/2018	0	-5	N/A	-3	N/A
3/31/2018	0	-6	N/A	-3	N/A
12/31/2017	0	-6	N/A	-2	N/A
9/30/2017	0	-5	N/A	-2	N/A
6/30/2017	0	-4	N/A	-2	N/A
3/31/2017	0	-3	N/A	-2	N/A
12/31/2016	0	-3	N/A	-2	N/A
9/30/2016	0	-2	N/A	-1	N/A
6/30/2016	0	-3	N/A	-1	N/A
3/31/2016	0	-3	N/A	-2	N/A
12/31/2015	0	-3	N/A	-1	N/A
9/30/2015	0	-3	N/A	-1	N/A
6/30/2015	0	-3	N/A	-1	N/A
3/31/2015	0	-3	N/A	-1	N/A
12/31/2014	0	-3	N/A	-1	N/A
9/30/2014	0	-2	N/A	-1	N/A
6/30/2014	0	-2	N/A	-1	N/A
3/31/2014	0	-2	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van NAOV boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van NAOV naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van NAOV naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van NAOV naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van NAOV naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NAOV naar verwachting over 3 jaar hoog zal zijn

NanoVibronix Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Third quarter 2024 earnings released: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023)

Nasdaq Notifies NanoVibronix Regarding Potential Delisting Due to Non-Compliance with Nasdaq Listing Rule 5550(a)(2)

NanoVibronix, Inc., Annual General Meeting, Dec 19, 2024

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.65 loss in 2Q 2023)

Insufficient new directors

NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan

NanoVibronix Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix Regains Nasdaq Compliance

Third quarter 2023 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2022)

NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff

NanoVibronix, Inc. announced that it expects to receive $5 million in funding

NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff

New minor risk - Share price stability

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.93 loss in 2Q 2022)

NanoVibronix Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.81 loss in 1Q 2022)

Full year 2022 earnings released: US$3.84 loss per share (vs US$11.35 loss in FY 2021)

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

Nanovibronix, Inc. Announces Interim Results of Clinical Study for UroShield

Third quarter 2022 earnings released: US$0.034 loss per share (vs US$0.26 loss in 3Q 2021)

Insufficient new directors

NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

NanoVibronix receives extension to satisfy Nasdaq bid price requirement

Insufficient new directors

NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

NanoVibronix, Inc., Annual General Meeting, Sep 14, 2022

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

Insufficient new directors

Nanovibronix, Inc. Announces FDA 510(K) Submission for Painshield MD Plus

NanoVibronix, Inc. Adds Additional Product to Federal Supply Schedule

NanoVibronix, Inc. announced delayed annual 10-K filing

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

NanoVibronix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

NanoVibronix Files Three U.S. Patent Applications Further Leveraging Its Innovative Surface Acoustic Wave Technology

NanoVibronix, Inc. Announces Positive Interim Results from Independent, Real World Patient Study of its UroShield

Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans?

Third quarter 2021 earnings released: US$0.25 loss per share (vs US$0.099 loss in 3Q 2020)

NanoVibronix, Inc. Launches New, Transdermal Gel Containing Nano-Cannabidiol for the Treatment of Joint Pain and Reducing Inflammation

NanoVibronix: Portable Ultrasonic Therapeutic Devices

Second quarter 2021 earnings released: US$0.009 loss per share (vs US$0.20 loss in 2Q 2020)

NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans

Nanovibronix, Inc Announces That the Therapeutic Goods Administration

Nanovibronix Announces Publication of Compelling Study Results for Uroshield in the Journal of Medical & Surgical Urology

NanoVibronix Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market

NanoVibronix, Inc. announced delayed 10-Q filing

NanoVibronix Receives Notice from Nasdaq for Not Complying with Continued Listing Rule

Nanovibronix Announces Expanded Cms Reimbursement Approval for Painshield

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix UroShield Joins PainShield on Federal Supply Schedule, Expanding Access to VA Market

NanoVibronix Regains Nasdaq Compliance

NanoVibronix, Inc. Enters into an Amended and Restated Distribution Agreement

NanoVibronix, Inc. Amends and Expands Distribution Agreement for its Painshield and Painshield Plus with Ultra Pain Products, Inc

NanoVibronix announces expansion of distribution pact for its ultrasound devices

NanoVibronix, Inc Announces Independent Study Finds Significant Benefits Provided by UroShield Device

NanoVibronix secures $6M in equity capital

NanoVibronix reports Q3 results

Nanovibronix Expands Offerings with Introduction of Painshield Plus

NanoVibronix, Inc. Announces Executive Changes

NanoVibronix, Inc. has completed a Follow-on Equity Offering in the amount of $1.794783 million.

NanoVibronix's UroShield® Receives U.S. Food and Drug Administration Authorization for Entry into the US

NanoVibronix, Inc. has completed a Follow-on Equity Offering in the amount of $3.250001 million.

NanoVibronix, Inc. announced delayed 10-Q filing

NanoVibronix, Inc. announced that it has received $0.1 million in funding from Aigh Capital Management, LLC

NanoVibronix, Inc. announced that it has received $0.2 million in funding from Globis Capital Management, LLC

NanoVibronix, Inc. announced delayed 10-Q filing

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven